{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T15:50:23Z","timestamp":1759333823749,"version":"build-2065373602"},"reference-count":19,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Ovarian cancer complicated with chylothorax is extremely rare, and only eight papers can be searched in PubMed. We report a case of advanced ovarian cancer with extensive lymphatic metastasis that led to chylothorax and then chylous ascites. Combined with the literature review, we try to identify its clinical characteristics.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case description<\/jats:title><jats:p>A 64-year-old patient with advanced ovarian cancer relapsed, presenting with extensive lymphatic metastasis and a right pleural effusion. Thoracentesis was performed. The drainage fluid had a milky white appearance with triglyceride levels &amp;gt;1.24 mmol\/L (110 mg\/dL), a cholesterol level &amp;lt;5.18 mmol\/L (200 mg\/dL), and a positive chyle test. A multi-disciplinary team recommended anti-tumor therapy for ovarian cancer and conservative treatment of chylothorax, including a strict diet with low-fat medium\u2013long-chain triglycerides and chest tube insertion with interleukin-2 intrapleural perfusion as the pleurodesis agent. Chylothorax improved significantly with progressively reduced and transparent pleural effusion. However, strict diet control affected her quality of life negatively, and the patient was not able to adhere to the diet plan. Therefore, chylothorax recurred, but chyle was produced slowly; thoracentesis was performed repeatedly with IL-2 or cisplatin pleural perfusion at intervals of 2\u20135 months (a total of six times) in March 2021\u2013June 2023. In June 2023, the patient was not able to tolerate systemic chemotherapy because of severe myelosuppression after fourth-line chemotherapy. The patient developed bilateral chylothorax and then chylous ascites in December 2023. Finally, the patient died in March 2024.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Ovarian cancer complicated with chylothorax is a rare condition with a relatively poor prognosis. Pleural fluid analysis can identify this condition when clinical suspicion exists. Anti-tumor treatment of ovarian cancer and conservative management of chylothorax were first recommended instead of surgery, which have been proven to be effective in treating OCC.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2025.1555038","type":"journal-article","created":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T04:11:18Z","timestamp":1759205478000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Chylothorax in a patient with advanced ovarian cancer: a case report and literature review"],"prefix":"10.3389","volume":"15","author":[{"given":"Qiuying","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaolan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ke","family":"Niu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenjie","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1097\/MPH.0b013e3181984dd3","article-title":"Serous cystadenocarcinoma of the ovary in an 11-year-old girl with extensive dissemination and chylothorax: a case report and a brief review of literature","volume":"31","author":"Gupta","year":"2009","journal-title":"J Pediatr Hematol Oncol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"100727","DOI":"10.1016\/j.gore.2021.100727","article-title":"Postoperative chest liver herniation after cardiophrenic lymph node resection by a transdiaphragmatic approach following primary cytoreductive surgery for advanced endometrioid ovarian cancer: A case report","volume":"36","author":"Leray","year":"2021","journal-title":"Gynecol Oncol Rep"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2017.09.001","article-title":"Feasibility, safety and clinical outcomes of cardiophrenic lymph node resection in advanced ovarian cancer","volume":"147","author":"Cowan","year":"2017","journal-title":"Gynecol Oncol"},{"key":"B4","article-title":"Chylothorax in a patient with ovarian tumour","volume":"47","author":"Gupta","year":"2005","journal-title":"Indian J Chest Dis Allied Sci"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-1018512","article-title":"Co-existent chylous and serous pleural effusions associated with ovarian cancer: a case report of Contarini\u2019s syndrome","volume":"11","author":"Lawton","year":"1985","journal-title":"Eur J Surg Oncol"},{"key":"B6","article-title":"M\u00e5ling af pH i pleurav\u00e6ske er af v\u00e6rdi ved udredning af \u00e5rsagen til purulent pleuraeffusion [Measuring pH in pleural fluid is valuable when identifying the cause of purulent pleural effusion","volume":"174","author":"Davidsen","year":"2012","journal-title":"Ugeskr Laeger"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.earlhumdev.2006.05.007","article-title":"Primary ovarian angiosarcoma\u2013review of the literature and report of a case with coexisting chylothorax","volume":"28","author":"Vavilis","year":"2007","journal-title":"Eur J Gynaecol Oncol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.rmed.2009.08.010","article-title":"Chylothorax: aetiology, diagnosis and therapeutic options","volume":"104","author":"McGrath","year":"2010","journal-title":"Respir Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejcts.2007.04.024","article-title":"Aetiology and management of chylothorax in adults","volume":"32","author":"Nair","year":"2007","journal-title":"Eur J Cardiothorac Surg"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3978\/j.issn.2072-1439.2011.09.03","article-title":"Chylothorax after blunt trauma","volume":"4","author":"Seitelman","year":"2012","journal-title":"J Thorac Dis"},{"key":"B11","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S0300-2977(99)00114-X","article-title":"Chylothorax","volume":"56","author":"de Beer","year":"2000","journal-title":"Neth J Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.97.10051157","article-title":"Chylothorax and pseudochylothorax","volume":"10","author":"Hillerdal","year":"1997","journal-title":"Eur Respir J"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.4065\/84.2.129","article-title":"Pleural fluid characteristics of chylothorax","volume":"84","author":"Maldonado","year":"2009","journal-title":"Mayo Clin Proc"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1259\/bjr\/64849421","article-title":"The effectiveness of lymphangiography as a treatment method for various chyle leakages","volume":"82","author":"Matsumoto","year":"2009","journal-title":"Br J Radiol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1C265","article-title":"Octreotide as a therapeutic option for management of chylothorax","volume":"37","author":"Al-Zubairy","year":"2003","journal-title":"Ann Pharmacother"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1378\/chest.114.3.731","article-title":"Medical thoracoscopic talc pleurodesis for chylothorax due to lymphoma: a case series","volume":"114","author":"Mares","year":"1998","journal-title":"Chest"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejcts.2008.03.050","article-title":"Persistent chylothorax in lymphangioleiomyomatosis treated by intrapleural instillation of povidone","volume":"34","author":"Rizzardi","year":"2008","journal-title":"Eur J Cardiothorac Surg"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.thorsurg.2015.07.014","article-title":"Postoperative chylothorax","volume":"25","author":"Martucci","year":"2015","journal-title":"Thorac Surg Clin"},{"key":"B19","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1016\/j.athoracsur.2011.10.060","article-title":"Postesophagectomy chylothorax: incidence, risk factors, and outcomes","volume":"93","author":"Shah","year":"2012","journal-title":"Ann Thorac Surg"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1555038\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T04:11:19Z","timestamp":1759205479000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1555038\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,30]]},"references-count":19,"alternative-id":["10.3389\/fonc.2025.1555038"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1555038","relation":{},"ISSN":["2234-943X"],"issn-type":[{"type":"electronic","value":"2234-943X"}],"subject":[],"published":{"date-parts":[[2025,9,30]]},"article-number":"1555038"}}